Patent Yard Sign in
Expired Canadian patentCanada

Assays and methods using biomarkers

CA 2575755 C · Owner: Wagner, Klaus W. · Inventors: Wagner, Klaus W.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed August 3, 2005 and granted April 8, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 3, 2025.
  • Certificates of supplementary protection extend only drug patents, and it isn't classified as one.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledAugust 3, 2005
GrantedApril 8, 2014
Term endedAugust 3, 2025
Patent numberCA 2575755 C
Classification (IPC)—

Timeline

Timeline From CIPO dates

2006200820102012201420162018202020222024Application filedAug 3, 2005Patent grantedApril 8, 2014Term endedAug 3, 2025

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.